Key Points Tilray's shares initially fell more than 12% shortly after the market opened on Tuesday. Monday's surge followed a video posted by President Trump promoting CBD for seniors, which sparked a sector-wide rally. Even after today's drop, the stock remains up sharply for the week. 10 stocks we like better than Tilray Brands › Shares of Tilray Brands (NASDAQ: TLRY) declined as much as 12.4% on Tuesday, but were down about 9% as of 10:30 a.m. ET. The pullback comes a day after a dramatic rall ...

Core Insights - The U.S. cannabis industry has rapidly expanded, generating over $33 billion in annual sales, with projections to exceed $56 billion by 2030, presenting significant opportunities for Canadian cannabis companies [1] - Canadian firms are strategically positioned to benefit from U.S. regulatory progress and increasing cross-border demand through scaling production, diversifying product lines, and investing in branded distribution [1][3] - Selecting cannabis stocks requires technical analysis for entry and exit points, alongside critical risk management practices to navigate high volatility [2] Company Summaries Tilray Brands - Tilray Brands has a growing international presence and has entered U.S. markets with hemp-derived THC products and beverage partnerships, establishing a strong retail distribution network [4][7] - In fiscal 2024, Tilray reported revenue of nearly $790 million but faced a net loss exceeding $220 million, although gross margins improved to around 41 percent in select segments [8][9] - The hemp-derived beverage segment is gaining traction, with sales of approximately $1.4 million, indicating potential for future growth as consumer adoption increases [9] Canopy Growth Corporation - Canopy Growth is recognized for its efforts to expand beyond Canada, focusing on wellness products and CBD while building licensing and product partnerships in the U.S. [10][12] - Recent financial results show a modest 4 percent year-over-year increase in Canadian cannabis revenue, with operating losses reduced to $18 million, marking significant progress [13][14] - The company has lowered its debt from nearly $600 million to just over $300 million, enhancing its financial stability and flexibility [14][15] Village Farms International - Village Farms has pivoted from greenhouse growing to cannabis, focusing on cultivation, processing, and export markets without relying on a retail network [15][17] - In Q2 2025, consolidated net sales increased by 12 percent year-over-year to nearly $60 million, with net income reaching nearly $10 million, indicating a strong turnaround [17][18] - The company expanded its cultivation footprint by over 500,000 square feet, potentially boosting capacity by one-third and driving future revenue growth [18][19] Market Overview - Canadian cannabis stocks are experiencing volatility but continue to attract investor interest, with Tilray, Canopy Growth, and Village Farms employing diverse strategies to navigate market challenges [19][20] - As of October 2025, these companies represent the diversity within the Canadian cannabis sector, with careful execution and risk management being critical for investors [20]

With New York dispensaries projected to surpass $4.4 billion in annual sales by 2027, CBDL secures a transformative partnership poised to generate multi-million-dollar revenues and accelerate nationwide expansion. SCOTTSDALE, AZ / ACCESS Newswire / September 30, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its operating subsidiary CBD Vault, today announced a game-changing client acquisition with Smoking Scholars, a premier dispensary located at 784 Allerton Ave in the Bronx, New York. ...

Tilray (TLRY) shares closed nearly 60% higher on Sept. 29 after President Donald Trump promoted cannabidiol’s (CBD) potential to “revolutionize senior healthcare” in a video posted on Truth Social. In his social media post, the U.S. president also said the hemp-derived medicinal compound could generate substantial – as much as $64 billion annually – in medical cost savings as well. More News from Barchart Following Monday’s rally, Tilray stock hit a new 52-week high of $1.86. www.barchart.com Why Trum ...

Shares of cannabis and CBD-related companies surged on Monday after US President Donald Trump posted on Truth Social that hemp-derived cannabidiol (CBD), especially in senior healthcare,  “could revolutionize” treatment by reducing disease progression and providing an alternative to prescription drugs.He further reiterated his administration is exploring reclassifying marijuana under federal law, a change that could ease criminal penalties and open broader market access.The market reacted strongly: Tilray B ...

SNDL Inc. (NASDAQ:SNDL) is among the hidden penny stocks to buy now. According to a recent disclosure with the SEC, Goldman Sachs Group Inc. has raised its position in SNDL Inc. (NASDAQ:SNDL) by 17.1% in the first quarter. After the purchase of 62,004 shares, the global investment bank now owns 424,317 shares of the company’s stock, translating to an investment of $598,000. The company’s year-to-date return has been nothing short of commendable. While the market delivered a return of 12.96%, SNDL Inc. ( ...

Market Overview - The market is experiencing fluctuations, with a notable bounce from session lows as the trading day comes to a close [1][2] - Investors are concerned about a potential government shutdown, which could impact upcoming economic data releases, including a jobs report [2][3] Seasonal Trends - Historically, this month was expected to be muted, yet the market has reached multiple record highs this year, raising questions about the sustainability of this trend [4][5] - Goldman Sachs analysts suggest a year-end rally is possible, supported by favorable market positioning and expectations for the upcoming earnings season [5][6] Market Performance - Major indices are showing positive movement, with the Dow Jones up approximately 0.1%, S&P 500 up about 0.25%, and NASDAQ composite up around 0.5% [6][7] - The S&P 500 saw 308 stocks gain ground, indicating a healthy breadth despite contained moves at the benchmark level [8] Sector Performance - Consumer discretionary and technology sectors are leading gains, while communication services and energy sectors showed minor declines [9] Notable Stock Movements - Applovin, a mobile app marketing company, saw a significant increase of about 11%, with analysts raising price targets substantially [10][11] - Cannabis stocks, particularly Tilray Brands, experienced a surge of approximately 61% following positive media coverage regarding CBD benefits [13] - Carnival Corporation reported record revenue and raised its earnings forecast, yet shares fell by 4% due to market reactions [17][18] - Beyond Meat shares plummeted by 36% after announcing a debt restructuring plan, marking a record low for the company [22] Earnings Reports - Vail Resorts reported a fourth-quarter loss that exceeded analyst expectations, contributing to a decline in stock value [26][28] - The company is facing challenges with decreased skier visits and a rough year overall, leading to a 20% year-to-date decline in stock price [28][30]

Core Insights - The article provides a market analysis of several cannabis companies, including Canopy Growth Corp, OrganiGram Holdings Inc, Aurora Cannabis Inc, and cbdMD Inc, highlighting their performance and market trends [1] Company Summaries - **Canopy Growth Corp**: The company has shown significant fluctuations in its stock price, reflecting broader market trends in the cannabis industry [1] - **OrganiGram Holdings Inc**: This company has been focusing on expanding its product offerings and improving operational efficiencies to enhance profitability [1] - **Aurora Cannabis Inc**: Aurora has been navigating challenges related to regulatory changes and market competition, impacting its growth strategy [1] - **cbdMD Inc**: cbdMD is positioning itself in the CBD market, emphasizing brand recognition and product quality to capture consumer interest [1] Industry Trends - The cannabis industry is experiencing increased competition, with companies striving to differentiate themselves through product innovation and branding [1] - Regulatory changes continue to shape the market landscape, influencing operational strategies and investment opportunities within the sector [1] - Consumer preferences are shifting towards high-quality and diverse product offerings, prompting companies to adapt their strategies accordingly [1]

Core Viewpoint - Canopy Growth (CGC) shares experienced an 18% increase following President Trump's endorsement of cannabidiol (CBD) as a potential breakthrough in senior healthcare, suggesting possible marijuana reclassification under his administration [1][3]. Market Reaction - Following the recent rally, Canopy Growth stock has risen over 100% compared to its year-to-date low [2]. Potential Impact of Reclassification - Trump's endorsement could lead to a shift in U.S. policy, allowing Canadian cannabis firms to access the U.S. market more freely, reduce tax burdens, and attract institutional capital [3]. - Reclassification would legitimize cannabis as a mainstream wellness product, potentially increasing demand and improving investor sentiment [4]. - Canopy Growth's existing stake in Acreage Holdings positions the company favorably for expansion and long-term revenue growth if regulatory reforms occur [4]. Financial Concerns - Despite positive sentiment, Canopy Growth continues to face significant financial challenges, including steep losses, negative EBITDA, and dwindling cash reserves [5]. - The company's core Canadian business is declining due to oversupply and price compression, and its U.S. exposure remains limited and dependent on uncertain federal reforms [6]. Wall Street Sentiment - Wall Street maintains a generally positive outlook on Canopy Growth, with a consensus rating of "Hold" and a mean target price of $2.38, indicating a potential upside of 50% [7].

Core Viewpoint - Organigram Global Inc (NASDAQ: OGI) shares are experiencing a significant increase due to renewed optimism in the cannabis sector following a social media post from former President Donald Trump promoting the health benefits of cannabis and hinting at potential changes in federal drug policy [1][2]. Company Overview - Organigram is a major Canadian cannabis producer with a diverse portfolio of recreational cannabis brands, including SHRED, Edison Cannabis Co., and Trailblazer [2]. - The company has expanded its e-commerce platform for hemp-derived THC beverages into 25 U.S. states, enhancing its market access and potential for growth [2]. Market Performance - As of the publication time, Organigram shares were up 15.09%, trading at $1.94 [3].